Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039273 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00039273 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 44 participants.
The verdict
NCT00039273, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic colorectal cancer.
Interventions
- BIOLOGICAL panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039273
The ClinicalTrials.gov registry entry for NCT00039273 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which panitumumab is the first listed.
NCT00039273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039273 about?
NCT00039273 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic co...
What is the current status of trial NCT00039273?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2002-07.
What interventions are being tested in trial NCT00039273?
The interventions under investigation include: panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00039273?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.